

**The Ohio State University Comprehensive Cancer Center –  
Arthur G. James Cancer Hospital and  
Richard J. Solove Research Institute**

**OSUCCC – James Clinical Trials Office (CTO) Leadership  
May 2012**

**Joyce Nancarrow Tull, RN, BSN, MS, CCRP (CTO Administrative Director)**

Joyce Nancarrow Tull has more than 35 years of experience in nursing, with one-third of her career invested in the care and support of people with cancer. Her varied work experiences include oncology clinical trials, adult and pediatric hospice, oncology/neurology/inpatient rehabilitation case management, mother/baby care, homecare, pediatrics and PICU, along with multiple progressive leadership roles. She earned her undergraduate degree from Mercy College of Detroit and went on to obtain a graduate degree in Nursing, Business and Health Systems from the University of Michigan. Most recently she served as director of Beaumont Health System's Community Clinical Oncology Program (CCOP: U10 Grant), Community Health Education Program, and Corporate Nurse Leader for the Oncology Service Line. Her research interests focus on identifying and ameliorating the historical, cultural and socioeconomic variables affecting enrollment in cancer clinical trials.

**Steven Devine, MD (CTO Medical Director for Hematologic Malignancies)**

Steven Devine, MD, is a professor in the Division of Hematology and director of the Blood and Marrow Transplant Program at Ohio State's Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC – James). He was recruited to Ohio State in 2005 from Washington University School of Medicine in St. Louis.

A member of the Experimental Therapeutics Program at the OSUCCC – James, Devine conducts research focusing on novel therapies involving the transplantation of adult blood-forming stem cells, and on allogeneic (donor) blood cell transplantation for treating advanced acute myeloid leukemia and myelodysplastic syndrome.

Devine graduated from the University of Massachusetts Medical School and trained in hematology/oncology at the University of Chicago and Emory University. He is a member of the American Society of Hematology, The International Society of Experimental Hematology and the American Society of Blood and Marrow Transplantation, where he recently served on the board of directors.

He has written or co-written more than 130 peer-reviewed papers on stem cell transplantation and hematology, and he has served as a reviewer for several journals, including *Blood*, *Nature Medicine*, *Biology of Blood and Marrow Transplantation*, *Experimental Hematology* and *Bone Marrow Transplantation*.

In 2010, Devine was named as chair of the Alliance (formerly Cancer and Leukemia Group B (CALGB)) transplant modality committee. This committee led a phase III study in multiple myeloma that was recently published in *The New England Journal of Medicine*. The Alliance is a cooperative group sponsored by the National Cancer Institute that performs clinical trials for patients with many types of cancers, with a focus on new molecular-targeted therapies, multidisciplinary treatment, pharmacogenomics and pharmacogenetics.



## OSUCCC – James Clinical Trials Office (CTO) Leadership May 2012

### **Buveneswari Ramaswamy, MD, MRCP (CTO Medical Director for Solid Tumors)**

Bhuvanewari Ramaswamy, MD, MRCP, is an assistant professor in the Division of Medical Oncology at Ohio State and a member of the Experimental Therapeutics Program at Ohio State's Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC – James).

Ramaswamy joined Ohio State's medical oncology faculty in July 2006 after having served since 2003 as an oncology fellow at the OSUCCC – James, where she also served as a breast cancer research fellow from 2002-03. Before that, she was a resident in internal medicine at Mount Carmel Medical Center (2000-02) and a research assistant in the Division of Hematology and Oncology at Vanderbilt University Medical Center in Nashville (1998-2000).

After joining the medical oncology faculty, she was a K-12 scholar recipient for three years and has received several peer-reviewed grants, including a Pelotonia "idea grant," an American Cancer Society pilot grant and grants from Ohio State's Center for Clinical and Translational Science (CCTS). She is a reviewer for several journals and a member of the national scientific review committee for the U.S. Department of Defense grants. She also serves on Ohio State's Clinical Scientific Review Committee, and she was named as one of America's top physicians in 2009 and 2011.

Ramaswamy's clinical research focuses mainly on breast cancer treatment, in particular drug resistance. She is involved with a number of clinical trials, including a phase I trial of PARP inhibitor ABT 888 and carboplatin in breast cancer, a phase II trial of trastuzumab, docetaxel and bevacizumab in breast cancer, and a pilot study with TLR9 agonist with trastuzumab in breast cancer.

Ramaswamy earned her MBBS (MD) in 1988 from Kilpauk Medical College at Madras University in India and her MRCP in 1991 from the Royal College of Physicians in Edinburgh, United Kingdom. She has published in numerous scientific journals.